w a Croatian Lab Peptide Saved My Shoulder, My Father's Hip, and My Friend's Fingers
What 30 years of Croatian research, a WADA ban, and my own avoided surgeries can teach us about the most polarizing peptide in biohacking.
As always, nothing in this article constitutes medical advice.
Research this alongside a qualified healthcare provider before making any decisions.
Everyone has an opinion about peptides these days — and BPC-157 is squarely at the center of the debate. In one corner: biohackers, functional medicine practitioners, and athletes swearing by its healing properties. In the other: skeptics citing the absence of large-scale human clinical trials, plus regulatory agencies that have either banned it outright or left it in a gray zone.
Here’s what I’ve noticed: most people talking about BPC-157 are missing critical context. The conversation gets flattened into “it works” versus “there’s no evidence,” and both sides tend to ignore the more interesting, more nuanced reality. Let me try to fix that.
My N=1: When the Science Becomes Personal
I want to be transparent about something before we dive into the research: I am not a neutral observer on BPC-157. I have used it, repeatedly, and the results in my own life have been striking enough that I feel an obligation to share them — while being equally clear that personal experience, however compelling, is not the same as controlled data.
Shoulder dislocation — surgery avoided. After a severe shoulder dislocation that caused significant tendon damage, I spent a full year working through every conventional protocol my doctors recommended. Nothing worked. I was scheduled for surgery. As a last resort, I began locally injecting BPC-157 daily for four weeks. The surgery was cancelled. I still have full function in that shoulder.
Broken ankle — back on my feet in 5 days. Following an ankle fracture, I injected BPC-157 twice daily, as close to the injury site as possible, combined with TB-500. Within five days I was walking without the boot. My orthopedist was puzzled. I was not.
My father — hip replacement avoided. My father was facing hip replacement surgery. He began a BPC-157 injection protocol. The surgery is no longer on the table.
A friend’s frostbitten fingers — near-amputation reversed. A friend suffered severe frostbite across three fingers, to the point where amputation was being discussed. Having nothing to lose, he started injecting BPC-157. He retained approximately 90% of his fingers.
Are these anecdotes? Yes.
Can they be dismissed as such from a scientific standpoint? Technically, yes.
But these are real people, real outcomes, and they are part of why I take this compound seriously and why I will continue to. N=1 data, when it accumulates consistently across multiple people and multiple tissue types, starts to look less like coincidence and more like signal.
🔬 A Note on Sourcing and Quality
If you decide to explore BPC-157, sourcing is everything. The gray-market peptide space is flooded with products of wildly variable purity and concentration. I only use Soma Peptides — their quality standards and third-party testing are what I trust for my own body and my family’s.
Use code
VALBIOHACKERat checkout for 10% off.Disclosure: I receive a commission on purchases made through this code. However, I only partner with brands I personally use. I ONLY use SOMA PEPTIDES for all my peptide needs.
What Is BPC-157, Actually?
BPC-157 — Body Protection Compound 157 — is a synthetic pentadecapeptide, meaning a chain of 15 amino acids. What makes it unusual is its origin: it was derived from a protective protein found naturally in human gastric juice. Your stomach already produces something related to this compound as part of its protective lining. Researchers isolated it, stabilized it, and began testing it for therapeutic applications.
The isolation and early research happened in Croatia, at the University of Zagreb, led by Dr. Predrag Sikiric and his team — and this is the first piece of crucial context most commentators skip entirely.
The Croatian Problem (and Why ClinicalTrials.gov Isn’t the Whole Story)
Here is the point I want to make very clearly: the absence of a compound on ClinicalTrials.gov does not mean it has never been studied in humans.
ClinicalTrials.gov is a U.S.-based registry, managed by the National Library of Medicine. It became mandatory for many trials only relatively recently, and it primarily reflects the research ecosystem of the United States and, to a lesser extent, other Western countries. It is not — and was never intended to be — a complete global database of all human research ever conducted.
BPC-157 research began in the early 1990s at the University of Zagreb. Croatian scientists, working within their own institutional and regulatory framework, were building a body of preclinical and early clinical data for decades before most Americans had heard of peptides. The Croatian pharmaceutical company Pliva — which at the time was one of the largest pharma companies in Central and Eastern Europe — sponsored clinical trials for BPC-157 (under drug names PL-10, PLD-116, and PL14736) as a treatment for inflammatory bowel disease in the late 1990s and early 2000s.
Phase I safety data from those trials indicated that BPC-157 administered rectally was safe and well-tolerated in healthy volunteers. Phase II trials in patients with mild-to-moderate ulcerative colitis were also initiated.
Are these trials on ClinicalTrials.gov? No. Did they happen? Yes.
The problem — and I want to be fair here — is that the peer-reviewed publications resulting from these trials appear never to have been indexed in major global databases like PubMed, and the full data was never made publicly available. That is a legitimate scientific criticism. Published, peer-reviewed data that can be scrutinized and replicated is the cornerstone of how medicine advances. The Croatian team’s transparency around these trial results has been incomplete, and that matters.
But incomplete data disclosure is a very different claim than “no human trials have ever been conducted.” Those two statements are not the same thing, and conflating them leads to misinformation.
The Funding Problem: Who Pays for Clinical Trials?
Let’s talk about how drug development actually works, because this is the core of why BPC-157 remains in regulatory limbo after three decades of promising research.
Large-scale Phase III clinical trials — the kind that lead to FDA or EMA approval — are extraordinarily expensive. We’re talking hundreds of millions of dollars. Who funds them? Almost exclusively: pharmaceutical companies that hold or expect to hold intellectual property that gives them market exclusivity upon approval.
This is not a conspiracy. It’s basic economics.
BPC-157 is a peptide derived from human gastric juice. Its synthesis is not particularly exotic. It has been around long enough that broad patent protection on the compound itself is difficult to establish. No major pharmaceutical company has determined that the investment required to run a large-scale Phase III trial would generate a sufficient return. Without that commercial incentive, the pipeline stalls.
This is not unique to BPC-157. Dozens of compounds — many of them genuinely interesting — never reach the clinical trial finish line because the funding logic doesn’t work out. Ivermectin, low-dose naltrexone, and a host of natural compounds have faced the same structural problem. Lack of a large trial does not equal lack of efficacy. It often means lack of a patent-protected profit motive.
Does this mean BPC-157 is proven to work? No. It means the absence of a large Phase III trial is not, by itself, evidence of failure. The two things are not synonymous.
What the Animal Data Actually Shows
Several hundred animal studies — primarily conducted by Sikiric’s group at Zagreb — have tested BPC-157 across a remarkable range of applications. The results have consistently shown beneficial effects on:
Gastrointestinal tissue healing (ulcers, IBD, fistulas, anastomosis healing)
Tendon-to-bone attachment repair
Muscle and ligament healing
Nerve regeneration
Bone fracture healing
Neurological models (Parkinson’s, serotonin syndrome, dopamine dysregulation)
Wound healing at multiple tissue levels
That’s an unusually broad profile. In pharmacology, a compound that claims to do everything is a red flag — unless the mechanism explains the breadth. In BPC-157’s case, the proposed mechanism involves modulation of the nitric oxide system, promotion of angiogenesis (new blood vessel formation), and interaction with growth factor pathways including VEGF. These are genuinely pleiotropic mechanisms, meaning they could logically affect multiple tissue types.
Independent researchers from universities in the U.S., UK, and Poland have published reviews in recent years largely corroborating that the preclinical data looks promising — while acknowledging the critical gap in robust human data.
One concern flagged by the Polish research team is worth noting: because BPC-157 promotes angiogenesis, there is a theoretical risk that it could accelerate tumor growth by improving oxygen delivery to cancerous tissue. This is not a confirmed finding, but it is a legitimate scientific question that deserves proper investigation. It is one more reason why rigorous human trials matter.
The WADA Ban: What It Actually Means (and What It Doesn’t)
Here is where I need to address something that drives me slightly crazy in how this is presented online: the fact that BPC-157 is on the WADA Prohibited List is often cited as either proof of its danger, or ignored entirely as if it’s irrelevant to non-athletes.
Both framings are wrong.
WADA — the World Anti-Doping Agency — added BPC-157 explicitly by name to its Prohibited List in 2022, under the S0 category: Non-Approved Substances.
This category covers any substance not approved by a recognized global health authority for human therapeutic use.
What the ban tells us:
WADA believed the compound had sufficient performance-enhancement potential to warrant inclusion — specifically around tissue repair, recovery, and potentially endurance. You don’t ban something that doesn’t do anything.
The ban is global — not just American. WADA is an international body. Its prohibited list applies to athletes competing in Olympic sports and all sports governed by WADA-signatory federations worldwide. Australia’s Sport Integrity agency enforces it. European sports federations enforce it. This is not a US-centric regulation.
The S0 category is specifically for substances with no regulatory approval — meaning the ban does not require proof that BPC-157 is dangerous. It requires only that it lacks formal approval. This is important: being banned by WADA and being dangerous are not the same thing.
What the ban does not tell us:
The WADA ban does not apply to non-athletes using BPC-157 outside of competitive sport contexts. For the average person exploring it for gut healing, injury recovery, or longevity purposes, WADA’s position is regulatory context — not a personal health ruling. Understanding the distinction matters.
For competitive athletes, however, the consequences are severe and real. A professional combat athlete received a two-year suspension after testing positive for BPC-157. No Therapeutic Use Exemption exists for this compound because it is not approved anywhere as a therapeutic agent.
The Regulatory Reality: Gray Zone, Not Black and White
Let’s be precise about legal status, because this varies considerably depending on where you are:
United States: BPC-157 is not FDA-approved. The FDA has also flagged it as a bulk drug substance that may present safety risks in compounding, citing concerns about immunogenicity and peptide purity in compounded preparations. It cannot be legally prescribed or sold as a supplement or drug. It circulates as a “research chemical” — a legal fiction that provides thin cover for what is, in practice, gray-market commerce.
Outside the United States: Regulatory status varies widely. In many countries, BPC-157 is not specifically regulated as a controlled substance, and it occupies a gray zone that is distinct from — and often more permissive than — the American framework. The US FDA’s position is not the global default.
This matters because a significant portion of online discourse about BPC-157 is written from an American regulatory perspective and presented as if it reflects universal law. It does not.
What We Honestly Don’t Know
Intellectual honesty requires acknowledging the genuine gaps:
We do not have published, peer-reviewed Phase II data showing efficacy in a specific human condition. The Croatian Pliva trials were never published in full. The 2015 oral BPC-157 trial registered on ClinicalTrials.gov (under the name Bepecin) claimed the compound was safe and well-tolerated — but no peer-reviewed paper was published with the data.
We do not have established safe human dosing ranges derived from controlled studies.
We do not know the long-term effects of sustained BPC-157 use in humans — including the theoretical angiogenesis-cancer question.
The primary research base is heavily concentrated in one lab, one group, one country. That is a reproducibility concern. Science advances through independent replication. When a single research group produces the overwhelming majority of studies on a compound, and conflict-of-interest disclosures have been questioned, that is a legitimate flag.
My Bottom Line as a Biohacker
BPC-157 is neither the miracle compound its most enthusiastic proponents claim nor the dangerous, evidence-free substance its harshest critics suggest.
It is a 30-year-old research compound with a substantial preclinical evidence base, some early human safety data that was never fully published, a plausible and interesting mechanism, and a funding problem that reflects the structural failures of pharmaceutical development — not necessarily a failure of the science itself.
The honest position is that we are waiting for the kind of rigorous, independent, transparent human trial data that would either confirm or refute what the animal studies suggest. That data may be a long time coming, given the economics of trial funding. In the meantime, those who choose to use BPC-157 are making an informed-risk decision with imperfect information — which is not entirely unlike many decisions in medicine and health optimization.
If you are a competitive athlete, the WADA position is clear and the consequences are real. Know your sport’s rules.
If you are not a competitive athlete and you are considering BPC-157 for a specific health purpose, understand that you are working in a gray zone: promising preclinical data, limited but not absent human safety data, no established dosing protocols, and no quality control on gray-market products. Source matters enormously. Purity matters enormously.
And the next time someone tells you that BPC-157 “has no human trials,” do them the favor of pointing out that ClinicalTrials.gov and the entire body of global biomedical research are not the same thing.
As always, nothing in this article constitutes medical advice.
Research this alongside a qualified healthcare provider before making any decisions.
Valérie Orsoni
Biohacker since 1998 | Longevity Expert
Instagram : @valerieorsoni
My fave brands + super promo codes here ==> ValerieOrsoni.com
My clean, vegan, made-in-the-USA supplement line ==> ZellNova
🎙 Longevity Leadership Conference – Verizon Innovation Lab, Los Angeles - Mar 18–19, 2026)
🎤 Sommet de l’HyperSanté, Paris (Mars 21-22, 2026)
🎤 Biohackers World Conference & Expo, Los Angeles (Mars 28-29, 2026)
🎙 Life Summit, Berlin (May 29-30, 2026)
🎙 Biohacking Week, Propriano (June 7-14, 2026)
🎤 RAADFest, Sedona (Sept 4-6, 2026)
🎙 HealthSpan Summit, Los Angeles (Oct 2–4, 2026)
🎙 Reclaiming Health & Longevity Symposium (El Salvador, Nov 8–9, 2026)